Induction of cellular apoptosis in human breast cancer by DLBS1425, a Phaleria macrocarpa compound extract, via downregulation of PI3-kinase/AKT pathway

Cancer Biology and Therapy

Volumn 10, Issue 8, 2010, Pages 814-823

  Tandrasasmita, Olivia M ^a,b   Lee, Jason S ^b   Baek, Sung Hee ^b   Tjandrawinata, Raymond R ^a  

^a Dexa Medica Group   (Indonesia)

^b Seoul National University   (South Korea)

Author keywords

Anti cancer effect; Apoptosis; Breast cancer; Mahkota dewa; Phaleria macrocarpa; PI3 K AKT pathway

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 9; PHALERIA MACROCARPA EXTRACT; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; PUMA PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL DIVISION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELLL STRAIN MDA MB 231; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MEDICINAL PLANT; MOLECULAR MECHANICS; NONHUMAN; PHALERIA MACROCARPA; PROTEIN PHOSPHORYLATION;

EID: 78049249375     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.8.13085     Document Type: Article

References (38)

1. Parton M, Dowsett M, Smith I. Studies of Apoptosis in breast cancer. BMJ 2001; 322:1528-32.
2. Kim KC, Kim JS, Son JK, Kim IG. Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by the Ganoderma lucidum and Duchesnea chrysantha extracts. Cancer Lett 2007; 246:210-7.
3. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Onco 2001; 13:453-62.
4. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005; 103:1551-60. (Pubitemid 40490015)
5. Yu SW, Wang H, Poitras MF. Mediation of poly(ADPribose) polymerase-1-dependent cell death by apoptosis inducing Factor. Science 2002; 297:259-63.
6. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 12:1001-12.
7. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7:989-1000.
8. Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005; 7:940-52.
9. Kurnia D, Akiyama K, Hayashi H. 29-Norcucurbitacin derivatives isolated from the Indonesian medicinal plant, Phaleria macrocarpa (Scheff.) Boerl. J Biosci Biotechnol Biochem 2008; 72:618-20.
10. Tjandrawinata RR, Arifin PF, Tandrasasmita OM, Rahmi D, Aripin A. In press. DLBS1425, a Phaleria macrocarpa (Scheff.) Boerl. extract confers anti proliferative and proapoptosis effects via eicosanoid pathway. J Exp Ther Oncol.
11. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96:4240-5.
12. Cain RJ, Ridley AJ. Phosphoinositide 3-kinases in cell migration. Biol Cell 2009; 101:13-29.
13. Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res 2010; 316:24-37.
14. Su DM, Zhang Q, Wang X, He P, Zhu YJ, Zhao J, et al. Types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol Cancer Ther 2009; 8:1-13.
15. Oshimi S, Zaima K, Matsuno Y, Hirasawa Y, Iizuka T, Studiawan H, et al. Studies on the constituents from the fruits of Phaleria macrocarpa. J Nat Med 2008; 62:207-10.
16. Prabhakat BT, Khanum SA, Jayashree K, Salimath BP, Shashikanth S. Anti tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells. J Bioorg Med Chem 14:435-46.
17. Auyeung KKW, Liu PL, Chan C, et al. Herbal Isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPAR. Cancer Invest 2008; 26:708-17.
18. Raina K, Rajamanickam S, Deep G, Singh M, Agarwal R, Agarwal C. Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. J Mol Cancer Ther 2008; 7:1258-67.
19. Faried A, Kurnia D, Faried LS, Usman N, Miyazaki T, Kato H, Kuwano H. Anticancer effect of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int J Oncol 2007; 30:605-13.
20. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22:7414-30.
21. St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NFκB/IκB pathway. Mol Cancer 2004; 3:7.
22. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature 2006; 441:424-30.
23. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009; 21:199-208.
24. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 2008; 105:13057-62.
25. Izhou X, Jiang G, Zhao A, Bondeva T, Hirszel P, Balla T. Inhibition of Na,K-ATPase Activates PI3 Kinase and Inhibits Apoptosis in LLC-PK1 Cells. Biochem Biophys Res Comm 2001; 285:46-51.
26. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62.
27. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44.
28. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28:1379-86.
29. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14:381-95.
30. Fujiwara Y, Kawada K, Takano D, Tanimura S, Ozaki K, Kohno M. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochem Biophys Res Comm 2006; 340:560-6.
31. Daikoku T, Dey SK. Two faces of PTEN. Nat Med 2008; 14:192-1193.
32. Uddin S, Hussain A, Al-Husein K, Platianias LC, Bhatia KG. Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway, Biochem Biophys Res Commun 2004; 320:932-8.
33. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nat Rev Drug Discov 2005; 4:988-1004.
34. Barber MA, Welch HC. PI3K and RAC signalling in leukocyte and cancer cell migration. Bull Cancer 2006; 93:44-52.
35. Howes AL, Chiang GG, Lang ES, Ho CB, Powls G, Vuorl K, Abraham R. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007; 6/9:2505-14.
36. Vivanco I, Sawyers CL. The Phosphatidylinositol-3- Kinase-Akt pathway in human cancer. Nature 2002; 2:489-501. (Pubitemid 37328931)
37. Carnero A, Blanco Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Target 2008; 8:187-98.
38. Shimamura H, Terada Y, Okado T, Hiroyuki T, Seiji I, Sei S. The PI3-Kinase-Akt Pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NFκB and Bad. J Am Soc Nephrol 2003; 14:1427-34. (Pubitemid 36687043)